newswire, breaking biotechnology and pharma news

Monday, January 31, 2011

Biotech/Pharma Stocks News; UV Flu Technologies (OTCBB: UVFT) Completes Acquisition of RxAir Industries

CENTERVILLE, MA � January 31, 2011 ( Newswire) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") is pleased to announce it has completed an agreement securing the acquisition of RxAir Industries, LLC, ("RxAir") headquartered in Dallas, Texas.
RxAir ( is a well-known and highly regarded manufacturer of high quality air purification equipment designed for applications within the medical and hospitality marketplace, and also includes products geared for specialized industrial applications, such as emergency preparedness.
The agreement includes a patented, trademarked product line, with national distributors and representatives, an extensive customer list, inventory, and all associated manufacturing equipment. The Company has been in business for 15 years, and existing sales include an installed base of several thousand units in over 1000 unique facilities nationwide, including over 400 hospitals. The Company's two main products, the RX3000, which is the Company's best seller, provides air purification coverage in spaces up to 2000 sq. ft, while the RX4500, also known as the "Smoke Handler," is the preferred choice of hospitality establishments nationwide. The unit protects spaces of up to 5000 sq. feet, and can be connected to existing ductwork. Both units can remove more than 99.97% of airborne contaminants and pathogens greater than 0.3 micrometers in size and are designed with exterior cabinetry able to match any d�cor. They combine multiple filter configurations, including HEPA, with germicidal UV lamps, making one of the most effective air purification systems in the world today.
"This acquisition will be operated as a subsidiary of UV Flu Technologies, and will provide a U.S. manufacturing base to aid our efforts in the pursuit of medical, hotel, casino, government and DoD contract opportunities, including military and government facilities," said Mr. John Lennon, President of UV Flu Technologies. "The enhanced product line will make us increasingly attractive to large US distributors, and increase our visibility within the hospital and hospitality marketplace. The larger models and coverage that the RxAir units add to our product line open up a whole new marketplace for us. Larger public spaces like school cafeterias, gaming areas, restaurants, gymnasiums, and construction sites are now just some of the many potential new targets for our products. We believe the synergies will be extraordinary and hope to significantly increase our revenue estimates for 2011 as a result. Once our residential model is introduced to the lineup in 2011 we are highly optimistic for increased traction across the entire segment."
Further details regarding the Company's business, acquisitions, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database. For more information, visit:
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: For sales:
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
SOURCE: UV Flu Technologies, Inc.
UV Flu Technologies (OTCBB: UVFT) is a showcase biotech stock on (please read disclosure and disclaimers)
Visit the showcase page on

Request info:

No comments:

Post a Comment